David M. Zahrieh

Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study

Derlis Gonzalez, Hadhami Ben Turkia, Elena Lukina et al. · American Journal of Hematology · 2012 · 84 citations · Full text

Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase

Ari Zimran, Gregory M. Pastores, Anna Tylki‐Szymańska et al. · American Journal of Hematology · 2012 · 61 citations · Full text

Gene Activation Technology, Autoimmune Disease, Immunodeficiencies +11

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Kenneth L. Kehl, David M. Zahrieh, Ping Yang et al. · JAMA Oncology · 2022 · 50 citations · Full text

Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma

Robert E. Schoen, Lisa A. Boardman, Marcia Cruz‐Correa et al. · Clinical Cancer Research · 2023 · 47 citations · Full text

Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction

Deborah Elstein, A. Joseph Foldes, David M. Zahrieh et al. · Blood Cells Molecules and Diseases · 2011 · 39 citations

Bone Disease, Nutrition, Type 1 +6